Goldman Sachs has raised alarms about the future of the obesity market, stating that growth potential is dwindling. These concerns follow hype around various weight-loss drugs in the market. Analyzing investment decisions in this sector becomes crucial as market conditions shift. Investors must consider whether the excitement surrounding these treatments can sustain itself over time. As Wall Street reassesses its outlook, understanding the long-term viability of these drugs can inform better investment strategies.